Price movement over the last 24 hours
Agilent Technologies Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Agilent Technologies Inc trades at $128.79 (market cap $37.04B), while iShares Core MSCI Emerging Markets ETF trades at $79.9. The key difference: Agilent Technologies Inc pays a 0.78% dividend while iShares Core MSCI Emerging Markets ETF pays none, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | IEMG | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $86.00 |
52-Week Low | $110.24 | $59.90 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
IEMG trades at $82.00, up 2.71% with strong bullish technical signals from moving averages. The ETF has delivered exceptional performance, surging 35% over the past year according to Fool - Investing News (2026-07-06), driven by its 40% technology weighting and exposure to emerging market growth. Recent news highlights IEMG's valuation discount to US equities and its focus on AI through South Korean and Taiwanese semiconductor stocks.
The outlook remains positive given emerging market growth potential and AI exposure, though risks include elevated volatility at 37% and concentration in tech stocks. Analyst sentiment is mixed with some recommending profit-taking after the strong rally, while others emphasize the long-term growth opportunity in undervalued emerging markets.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →